What is Cambium Bio?
Cambium Bio operates at the intersection of advanced biotechnology and clinical ophthalmology. The company specializes in the development of innovative biologics derived from human platelet lysate, a proprietary technology designed to facilitate tissue regeneration. By focusing on the ocular space, Cambium Bio addresses complex conditions that have historically lacked effective, non-invasive treatment options. Their market position is defined by a robust research-driven approach, utilizing human-derived products to ensure safety and efficacy in cell therapy applications. As a clinical-stage enterprise, the company bridges the gap between laboratory-scale innovation and commercial-grade therapeutic production, positioning itself as a key player in the global regenerative medicine landscape.
How much funding has Cambium Bio raised?
Cambium Bio has raised a total of $9.6M across 1 funding round:
Private Equity
$1.9M
Private Equity (2024): $1.9M with participation from AventaCell BioMedical and Zheng Yang Biomedical Technology
Key Investors in Cambium Bio
AventaCell BioMedical
AventaCell BioMedical Corp is a leading developer of innovative human-derived products for cell culture and tissue regeneration, specializing in animal serum-free solutions for cell therapy.
Zheng Yang Biomedical Technology
Zheng Yang Biomedical Technology Co., Ltd. is an expert in oral healthcare and clinical cell therapy, focusing on regenerative capabilities and advanced ocular treatment development.
What's next for Cambium Bio?
Looking ahead, the strategic deployment of $1.9M will likely focus on the expansion of clinical trial infrastructure and the acceleration of its lead ophthalmology assets. With the support of key industry partners, Cambium Bio is expected to prioritize the progression of its FDA-aligned clinical programs, specifically targeting moderate to severe dry eye syndrome and other degenerative ocular conditions. The company's roadmap includes scaling its manufacturing processes to meet potential commercial demand while maintaining the rigorous quality standards required for biologics. By fostering collaborative research initiatives and optimizing its proprietary technology, Cambium Bio aims to solidify its leadership in the regenerative medicine sector, ultimately seeking to deliver transformative outcomes for patients worldwide.
See full Cambium Bio company page
